Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.67 |
| ▸ | PPARG | P37231 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | F9 | P00740 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27388673 | 0.89 | PPARA (0.72) | PPARAPPARGGAAKDM4EHSD17B10 | |
| SCHEMBL12504047 | 0.88 | PPARA (0.71) | PPARAPPARGGAAKDM4EHSD17B10 | |
| SCHEMBL4432959 | 0.87 | PPARA (0.69) | PPARAPPARGGAAKDM4EHSD17B10 | |
| SCHEMBL9863137 | 0.86 | PPARA (0.67) | PPARAPPARGGAAKDM4EHSD17B10 | |
| SCHEMBL10904428 | 0.85 | PPARA (0.67) | PPARAPPARGGAAKDM4EHSD17B10 | |
| SCHEMBL12406953 | 0.85 | PPARA (0.67) | PPARAPPARGGAAKDM4EHSD17B10 | |
| SCHEMBL1910455 | 0.85 | PPARA (0.67) | PPARAPPARGGAAKDM4EHSD17B10 | |
| SCHEMBL4082494 | 0.85 | ALDH1A1 (0.51) | PPARAPPARGGAAALDH1A1 | |
| SCHEMBL2731682 | 0.84 | PPARA (0.66) | PPARAPPARGGAAKDM4EHSD17B10 | |
| SCHEMBL14882747 | 0.83 | PPARA (0.68) | PPARAPPARGGAAKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111491623-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| WO-2016057660-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1768960-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | disclosed |
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | US | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| US-6660759-B1 | 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-12-09 | — | — | US | disclosed |
| US-6300344-B1 | FOR THERAPEUTIC AND/OR PROPHYLACTIC TREATMENT OF ARTERIAL OBSTRUCTION, CEREBROVASCULAR DISEASE, HEPATIC CIRRHOSIS, ARTERIOSCLEROSIS, ISCHEMIC HEART DISEASE, RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, HYPERTENSION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-09 | — | — | US | disclosed |
| WO-2001016132-A1 | 4,5-DIARYLOXAZOLE COMPOUNDS WITH PROSTAGLANDIN 12 (PG12) AGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-08 | — | — | WO | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5972965-A | USEFUL FOR INHIBITION OF PLATELET AGGREGATION, VASODILATION, ANTIHYPERTENSIVE ACTIVITY AND PROSTAGLANDIN AGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| EP-0842161-A1 | 4,5-DIARYL OXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997003973-A1 | 4,5-DIARYL OXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
| EP-0142324-B1 | PHENYLALKANOIC ACID DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-01-04 | — | — | EP | disclosed |
| US-4668698-A | [(4-phenyl-1,3-dioxan-cis-5-yl)alkyl]phenylalkanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-26 | — | — | US | disclosed |
| EP-0142324-A2 | Phenylalkanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | BACE1, APP, BACE2 | PPARA 1453/4885PPARG 2141/4885GAA 2302/4885 |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | PPARA 2767/4885PPARG 646/4885GAA 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.